RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Shin Nippon Biomedical Laboratories Equity 2024

Shin Nippon Biomedical Laboratories Equity

34.11 B JPY

Shin Nippon Biomedical Laboratories Dividend yield

2.21 %

Ticker

2395.T

ISIN

JP3379950003

WKN

A0BMJN

In 2024, Shin Nippon Biomedical Laboratories's equity was 34.11 B JPY, a 74.4% increase from the 19.56 B JPY equity in the previous year.

Shin Nippon Biomedical Laboratories Aktienanalyse

What does Shin Nippon Biomedical Laboratories do?

Shin Nippon Biomedical Laboratories Ltd (SNBL) is a Japanese company that was founded in 1957. The company is headquartered in Tokyo, Japan. SNBL is an important player in the research and development industry, offering a wide range of services in the field of biomedical research. SNBL's business strategy is based on providing services to pharmaceutical companies and other medical institutions. The service portfolio includes both the development phase and the approval and post-marketing monitoring of drugs. SNBL offers a comprehensive service in this area, ranging from experimental planning to study implementation, report creation, and results analysis. The company has several geographical offices in Asia, Europe, and America to serve its customers worldwide. SNBL is divided into different divisions specializing in different areas of biomedical research. One important division is the Non-human Primates (NHP) research program. SNBL is able to provide a wide range of NHP species for research, ranging from rhesus monkeys to monkeys from China and Africa. These animals are used for research projects both for drug safety assessment and disease exploration. SNBL is also active in the field of genetic engineering, offering a wide range of services in this area. The company has several cell-based assay systems for drug development and experience in producing recombinant proteins for research. SNBL also offers analysis services for nucleic acids and proteins of all kinds and has extensive expertise in genotyping and gene expression analysis. Another pillar of SNBL's activities is toxicology and safety research. SNBL is a leading provider of toxicology studies, advising its clients on the design of animal safety assessment studies. The company also provides a wide range of non-GLP studies for toxicity evaluations. Additionally, SNBL is able to evaluate the results of toxicology studies and conduct risk analyses for specific products. SNBL also has its own drug development pipeline and has several products in development. One example is Nafamostat Mesilate, a drug being developed for the treatment of acute respiratory distress syndrome and acute pancreatitis. The company works closely with its clients to develop customized solutions for their specific research needs. SNBL's products and services make a significant contribution to the biomedical research industry and have worldwide impact on the healthcare of humans and animals. The company has a long history in the research industry and is recognized as a provider of services for drug development due to its expertise and experience. With its extensive services for biomedical research, SNBL will remain an important player in this field in the future. Shin Nippon Biomedical Laboratories ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Shin Nippon Biomedical Laboratories's Equity

Shin Nippon Biomedical Laboratories's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Shin Nippon Biomedical Laboratories's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Shin Nippon Biomedical Laboratories's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Shin Nippon Biomedical Laboratories's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Shin Nippon Biomedical Laboratories’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Shin Nippon Biomedical Laboratories Stock

What is the equity of Shin Nippon Biomedical Laboratories this year?

Shin Nippon Biomedical Laboratories has equity of 34.11 B JPY this year.

What was the equity of Shin Nippon Biomedical Laboratories compared to the previous year?

The equity of Shin Nippon Biomedical Laboratories has increased/decreased by 74.4% increased compared to the previous year.

What impact does a high equity have on investors of Shin Nippon Biomedical Laboratories?

A high equity is advantageous for investors of Shin Nippon Biomedical Laboratories as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Shin Nippon Biomedical Laboratories?

A low equity can be a risk for investors of Shin Nippon Biomedical Laboratories, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Shin Nippon Biomedical Laboratories affect the company?

An increase in equity of Shin Nippon Biomedical Laboratories can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Shin Nippon Biomedical Laboratories affect the company?

A reduction in equity of Shin Nippon Biomedical Laboratories can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Shin Nippon Biomedical Laboratories?

Some factors that can affect the equity of Shin Nippon Biomedical Laboratories include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Shin Nippon Biomedical Laboratories so important for investors?

The equity of Shin Nippon Biomedical Laboratories is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Shin Nippon Biomedical Laboratories take to change the equity?

To change equity, Shin Nippon Biomedical Laboratories can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Shin Nippon Biomedical Laboratories pay?

Over the past 12 months, Shin Nippon Biomedical Laboratories paid a dividend of 30 JPY . This corresponds to a dividend yield of about 2.21 %. For the coming 12 months, Shin Nippon Biomedical Laboratories is expected to pay a dividend of 39.34 JPY.

What is the dividend yield of Shin Nippon Biomedical Laboratories?

The current dividend yield of Shin Nippon Biomedical Laboratories is 2.21 %.

When does Shin Nippon Biomedical Laboratories pay dividends?

Shin Nippon Biomedical Laboratories pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Shin Nippon Biomedical Laboratories?

Shin Nippon Biomedical Laboratories paid dividends every year for the past 9 years.

What is the dividend of Shin Nippon Biomedical Laboratories?

For the upcoming 12 months, dividends amounting to 39.34 JPY are expected. This corresponds to a dividend yield of 2.9 %.

In which sector is Shin Nippon Biomedical Laboratories located?

Shin Nippon Biomedical Laboratories is assigned to the 'Health' sector.

Wann musste ich die Aktien von Shin Nippon Biomedical Laboratories kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Shin Nippon Biomedical Laboratories from 6/1/2024 amounting to 30 JPY, you needed to have the stock in your portfolio before the ex-date on 3/28/2024.

When did Shin Nippon Biomedical Laboratories pay the last dividend?

The last dividend was paid out on 6/1/2024.

What was the dividend of Shin Nippon Biomedical Laboratories in the year 2023?

In the year 2023, Shin Nippon Biomedical Laboratories distributed 50 JPY as dividends.

In which currency does Shin Nippon Biomedical Laboratories pay out the dividend?

The dividends of Shin Nippon Biomedical Laboratories are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Shin Nippon Biomedical Laboratories

Our stock analysis for Shin Nippon Biomedical Laboratories Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Shin Nippon Biomedical Laboratories Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.